|
|
Article: Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases.
- Article from:
- PR Newswire
- Article date:
- February 20, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla., Feb. 20 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today announced that it has entered into an exclusive licensing agreement with Bridge Pharma, Inc. of Sarasota, FL for the worldwide rights to develop and market topical ophthalmic formulations containing Bridge Pharma's proprietary anti- inflammatory agent norketotifen.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )
"This agreement represents yet another significant milestone for Sirion. We are very excited about the medical and market potential of the norketotifen molecule," said Roger Vogel, MD, Chief ...
Related newspaper, magazine, and journal articles:
|
|
Article: Sirion Therapeutics Initiates Enrollment of Phase ...
PR Newswire;
January 22, 2007 ;
700+ words
... ... Jan. 22 /PRNewswire/ -- Sirion Therapeutics, Inc., an ophthalmic-focused ... President and Chief Executive Officer of Sirion Therapeutics, Inc. The company recently announced ... year," concluded Butler. About Sirion Therapeutics, Inc. and Sirion Holdings, Inc ...
|
|